Galmed Pharmaceuticals Ownership
| GLMD Stock | USD 2.86 0.01 0.35% |
Shares in Circulation | First Issued 2012-12-31 | Previous Quarter 524.6 K | Current Value 69.1 K | Avarage Shares Outstanding 1.7 M | Quarterly Volatility 3.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Galmed |
Galmed Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 0.26. Some equities with similar Price to Book (P/B) outperform the market in the long run. Galmed Pharmaceuticals recorded earning per share (EPS) of 69.72. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 30th of August 2024. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. To learn more about Galmed Pharmaceuticals call Allen Baharaff at 972 3 693 8448 or check out https://www.galmedpharma.com.Galmed Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Galmed Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Galmed Pharmaceuticals backward and forwards among themselves. Galmed Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Galmed Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Zrc Wealth Management, Llc | 2024-09-30 | 1.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 | Two Sigma Advisers, Llc | 2024-06-30 | 0.0 | Walleye Trading Advisors, Llc | 2024-06-30 | 290.6 K | Cvi Holdings Llc | 2024-06-30 | 47.2 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 36.2 K | Susquehanna International Group, Llp | 2024-06-30 | 11.6 K | Two Sigma Securities, Llc | 2024-06-30 | 10.3 K | Ubs Group Ag | 2024-06-30 | 280 | Wells Fargo & Co | 2024-06-30 | 204 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 167 |
Galmed Pharmaceuticals Outstanding Bonds
Galmed Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Galmed Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Galmed bonds can be classified according to their maturity, which is the date when Galmed Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Galmed Pharmaceuticals Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 28th of October 2024 Other Reports | ViewVerify | |
6K | 21st of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 20th of September 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 69.72 | Return On Assets (0.29) | Return On Equity (0.53) |
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.